Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 19, 2023 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 184,361 | -- | 184,361 | |
| Jul 14, 2020 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 160,237 | -- | 160,237 | |
| Jul 19, 2023 | Director, President and CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 108,871 | -- | -- | |
| Jul 19, 2023 | Director, President and CEO | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 108,871 | -- | -- | |
| Jul 14, 2020 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 108,871 | -- | 108,871 | |
| Dec 27, 2004 | Director | Form 4 | Open market or private sale of non-derivative or derivative security | 102,806 | $19.43 | -- | |
| Aug 18, 2016 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 100,000 | |
| Feb 01, 2013 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 100,000 | |
| Oct 18, 2011 | SVP, GM - Vascular | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 100,000 | |
| May 13, 2005 | Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 100,000 | $4.35 | 113,789 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.